Tusk Therapeutics Ltd

Royaume‑Uni

 
Quantité totale PI 31
Rang # Quantité totale PI 46 909
Note d'activité PI 2/5.0    15
Rang # Activité PI 57 573
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

13 0
2 0
15 0
1
 
Dernier brevet 2024 - Anti-cd25 antibody agents
Premier brevet 2018 - Method of treating cancer or dep...
Dernière marque 2018 - TUSK THERAPEUTICS
Première marque 2018 - TUSK THERAPEUTICS

Industrie (Classification de Nice)

Derniers inventions, produits et services

2023 Invention Anti-cd25 antibody agents. The present disclosure provides antibody sequences found in antibodie...
2019 Invention Anti-cd25 antibody agents. The present disclosure provides antibody sequences found in antibodies...
Invention Anti-cd25 for tumour specific cell depletion. The present disclosure provides antibody sequences ...
2018 Invention Cd38 modulating antibody. The present disclosure provides antibody sequences found in antibodies ...
Invention Cd38 antibody. The present disclosure provides antibody sequences found in antibodies that bind t...
Invention Compounds and methods for tumour-specific cell depletion. The present disclosure relates to use o...
Invention Cd38 modulating antibody. The present disclosure provides antibodies that bind to human CD38. In ...
P/S Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the trea...
Invention Fc-optimized anti-cd25 for tumour specific cell depletion. The present disclosure relates to use ...
Invention Method of treating cancer or depleting regulatory t cells in a subject by administering a human i...